nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—LYN—systemic lupus erythematosus	0.287	0.635	CbGaD
Nilotinib—BLK—systemic lupus erythematosus	0.165	0.365	CbGaD
Nilotinib—UGT1A1—Mycophenolate mofetil—systemic lupus erythematosus	0.0261	0.114	CbGbCtD
Nilotinib—ABCG2—Leflunomide—systemic lupus erythematosus	0.0232	0.101	CbGbCtD
Nilotinib—ABCG2—Mycophenolate mofetil—systemic lupus erythematosus	0.0143	0.0625	CbGbCtD
Nilotinib—ABCG2—Hydrocortisone—systemic lupus erythematosus	0.0115	0.0502	CbGbCtD
Nilotinib—ABCG2—Cyclosporine—systemic lupus erythematosus	0.0109	0.0474	CbGbCtD
Nilotinib—CYP2C8—Dapsone—systemic lupus erythematosus	0.00881	0.0384	CbGbCtD
Nilotinib—CYP2C9—Leflunomide—systemic lupus erythematosus	0.00863	0.0376	CbGbCtD
Nilotinib—CYP2C8—Mycophenolate mofetil—systemic lupus erythematosus	0.00764	0.0333	CbGbCtD
Nilotinib—ABCG2—Dexamethasone—systemic lupus erythematosus	0.00716	0.0312	CbGbCtD
Nilotinib—ABCB1—Methylprednisolone—systemic lupus erythematosus	0.00683	0.0297	CbGbCtD
Nilotinib—CYP2C9—Dapsone—systemic lupus erythematosus	0.00615	0.0268	CbGbCtD
Nilotinib—CYP2C8—Hydrocortisone—systemic lupus erythematosus	0.00613	0.0267	CbGbCtD
Nilotinib—CYP2C8—Cyclosporine—systemic lupus erythematosus	0.00579	0.0252	CbGbCtD
Nilotinib—ABCG2—Methotrexate—systemic lupus erythematosus	0.00575	0.0251	CbGbCtD
Nilotinib—ABCB1—Mycophenolate mofetil—systemic lupus erythematosus	0.00517	0.0225	CbGbCtD
Nilotinib—CYP2B6—Dexamethasone—systemic lupus erythematosus	0.00504	0.0219	CbGbCtD
Nilotinib—ABCB1—Betamethasone—systemic lupus erythematosus	0.00444	0.0193	CbGbCtD
Nilotinib—ABCB1—Prednisolone—systemic lupus erythematosus	0.00438	0.0191	CbGbCtD
Nilotinib—ABCB1—Hydrocortisone—systemic lupus erythematosus	0.00415	0.0181	CbGbCtD
Nilotinib—ABCB1—Prednisone—systemic lupus erythematosus	0.00414	0.018	CbGbCtD
Nilotinib—CYP3A4—Methylprednisolone—systemic lupus erythematosus	0.00409	0.0178	CbGbCtD
Nilotinib—CYP2C9—Cyclosporine—systemic lupus erythematosus	0.00404	0.0176	CbGbCtD
Nilotinib—ABCB1—Cyclosporine—systemic lupus erythematosus	0.00392	0.0171	CbGbCtD
Nilotinib—CYP2C8—Dexamethasone—systemic lupus erythematosus	0.00381	0.0166	CbGbCtD
Nilotinib—CYP2D6—Cyclosporine—systemic lupus erythematosus	0.00369	0.0161	CbGbCtD
Nilotinib—CYP3A4—Dapsone—systemic lupus erythematosus	0.00357	0.0156	CbGbCtD
Nilotinib—CYP3A4—Triamcinolone—systemic lupus erythematosus	0.0031	0.0135	CbGbCtD
Nilotinib—CYP3A4—Mycophenolate mofetil—systemic lupus erythematosus	0.0031	0.0135	CbGbCtD
Nilotinib—Ponatinib—LYN—systemic lupus erythematosus	0.00302	0.952	CrCbGaD
Nilotinib—CYP2C9—Dexamethasone—systemic lupus erythematosus	0.00266	0.0116	CbGbCtD
Nilotinib—CYP3A4—Betamethasone—systemic lupus erythematosus	0.00266	0.0116	CbGbCtD
Nilotinib—CYP3A4—Prednisolone—systemic lupus erythematosus	0.00262	0.0114	CbGbCtD
Nilotinib—ABCB1—Dexamethasone—systemic lupus erythematosus	0.00258	0.0113	CbGbCtD
Nilotinib—CYP3A4—Hydrocortisone—systemic lupus erythematosus	0.00249	0.0108	CbGbCtD
Nilotinib—CYP3A4—Prednisone—systemic lupus erythematosus	0.00248	0.0108	CbGbCtD
Nilotinib—CYP2D6—Dexamethasone—systemic lupus erythematosus	0.00243	0.0106	CbGbCtD
Nilotinib—CYP3A4—Cyclosporine—systemic lupus erythematosus	0.00235	0.0102	CbGbCtD
Nilotinib—CYP2C9—cardial valve—systemic lupus erythematosus	0.00219	0.0324	CbGeAlD
Nilotinib—ABCB1—Methotrexate—systemic lupus erythematosus	0.00207	0.00904	CbGbCtD
Nilotinib—CYP3A4—Dexamethasone—systemic lupus erythematosus	0.00155	0.00674	CbGbCtD
Nilotinib—MAPK8—endothelium—systemic lupus erythematosus	0.00133	0.0196	CbGeAlD
Nilotinib—TIE1—endothelium—systemic lupus erythematosus	0.00115	0.017	CbGeAlD
Nilotinib—UGT1A1—urine—systemic lupus erythematosus	0.00113	0.0166	CbGeAlD
Nilotinib—LYN—blood plasma—systemic lupus erythematosus	0.00109	0.0161	CbGeAlD
Nilotinib—EPHB4—endothelium—systemic lupus erythematosus	0.0008	0.0118	CbGeAlD
Nilotinib—TEK—endothelium—systemic lupus erythematosus	0.000766	0.0113	CbGeAlD
Nilotinib—MAPK14—blood plasma—systemic lupus erythematosus	0.00075	0.0111	CbGeAlD
Nilotinib—MAPK8—connective tissue—systemic lupus erythematosus	0.000628	0.00928	CbGeAlD
Nilotinib—FRK—lymphoid tissue—systemic lupus erythematosus	0.000603	0.00889	CbGeAlD
Nilotinib—UGT1A1—blood plasma—systemic lupus erythematosus	0.000588	0.00868	CbGeAlD
Nilotinib—BLK—lymphoid tissue—systemic lupus erythematosus	0.000581	0.00858	CbGeAlD
Nilotinib—LYN—connective tissue—systemic lupus erythematosus	0.00058	0.00856	CbGeAlD
Nilotinib—CDC42BPB—cortex of kidney—systemic lupus erythematosus	0.000576	0.0085	CbGeAlD
Nilotinib—EPHB2—lymphoid tissue—systemic lupus erythematosus	0.000575	0.00849	CbGeAlD
Nilotinib—MAPK8—skin of body—systemic lupus erythematosus	0.000567	0.00838	CbGeAlD
Nilotinib—KIT—endothelium—systemic lupus erythematosus	0.000555	0.00819	CbGeAlD
Nilotinib—CSF1R—blood plasma—systemic lupus erythematosus	0.000542	0.00801	CbGeAlD
Nilotinib—MAPK8—kidney—systemic lupus erythematosus	0.000535	0.0079	CbGeAlD
Nilotinib—MAPK8—cortex of kidney—systemic lupus erythematosus	0.000521	0.00769	CbGeAlD
Nilotinib—KIT—blood plasma—systemic lupus erythematosus	0.000493	0.00727	CbGeAlD
Nilotinib—CDC42BPB—tendon—systemic lupus erythematosus	0.000478	0.00705	CbGeAlD
Nilotinib—CYP2C9—urine—systemic lupus erythematosus	0.000473	0.00699	CbGeAlD
Nilotinib—MAPK8—lymphoid tissue—systemic lupus erythematosus	0.00046	0.00678	CbGeAlD
Nilotinib—CA1—blood plasma—systemic lupus erythematosus	0.000451	0.00665	CbGeAlD
Nilotinib—EPHB2—nervous system—systemic lupus erythematosus	0.000439	0.00648	CbGeAlD
Nilotinib—MAPK8—tendon—systemic lupus erythematosus	0.000432	0.00638	CbGeAlD
Nilotinib—CA3—connective tissue—systemic lupus erythematosus	0.000428	0.00631	CbGeAlD
Nilotinib—LYN—lymphoid tissue—systemic lupus erythematosus	0.000424	0.00626	CbGeAlD
Nilotinib—EPHB2—central nervous system—systemic lupus erythematosus	0.000423	0.00624	CbGeAlD
Nilotinib—EPHA8—nervous system—systemic lupus erythematosus	0.000421	0.00621	CbGeAlD
Nilotinib—CDC42BPB—lung—systemic lupus erythematosus	0.000419	0.00619	CbGeAlD
Nilotinib—MAPK8—bone marrow—systemic lupus erythematosus	0.000418	0.00618	CbGeAlD
Nilotinib—MAP4K1—lymphoid tissue—systemic lupus erythematosus	0.000418	0.00617	CbGeAlD
Nilotinib—EPHA8—central nervous system—systemic lupus erythematosus	0.000405	0.00598	CbGeAlD
Nilotinib—MAPK14—connective tissue—systemic lupus erythematosus	0.000399	0.00589	CbGeAlD
Nilotinib—EPHA3—lung—systemic lupus erythematosus	0.000397	0.00587	CbGeAlD
Nilotinib—CA7—kidney—systemic lupus erythematosus	0.000397	0.00586	CbGeAlD
Nilotinib—MAP4K1—tendon—systemic lupus erythematosus	0.000393	0.0058	CbGeAlD
Nilotinib—MAPK11—nervous system—systemic lupus erythematosus	0.000391	0.00578	CbGeAlD
Nilotinib—CDC42BPB—nervous system—systemic lupus erythematosus	0.000388	0.00573	CbGeAlD
Nilotinib—MAP4K1—bone marrow—systemic lupus erythematosus	0.00038	0.00561	CbGeAlD
Nilotinib—MAPK8—lung—systemic lupus erythematosus	0.000379	0.0056	CbGeAlD
Nilotinib—EPHB4—connective tissue—systemic lupus erythematosus	0.000378	0.00559	CbGeAlD
Nilotinib—MAPK11—central nervous system—systemic lupus erythematosus	0.000377	0.00556	CbGeAlD
Nilotinib—CDC42BPB—central nervous system—systemic lupus erythematosus	0.000374	0.00552	CbGeAlD
Nilotinib—EPHA3—nervous system—systemic lupus erythematosus	0.000368	0.00543	CbGeAlD
Nilotinib—EPHB4—nephron tubule—systemic lupus erythematosus	0.000367	0.00541	CbGeAlD
Nilotinib—TEK—connective tissue—systemic lupus erythematosus	0.000362	0.00535	CbGeAlD
Nilotinib—CYP3A4—urine—systemic lupus erythematosus	0.000361	0.00533	CbGeAlD
Nilotinib—MAPK14—skin of body—systemic lupus erythematosus	0.00036	0.00532	CbGeAlD
Nilotinib—EPHA2—nephron tubule—systemic lupus erythematosus	0.00036	0.00531	CbGeAlD
Nilotinib—BRAF—tendon—systemic lupus erythematosus	0.000359	0.0053	CbGeAlD
Nilotinib—CYP2D6—urine—systemic lupus erythematosus	0.000355	0.00524	CbGeAlD
Nilotinib—EPHA3—central nervous system—systemic lupus erythematosus	0.000354	0.00523	CbGeAlD
Nilotinib—MAPK8—nervous system—systemic lupus erythematosus	0.000351	0.00518	CbGeAlD
Nilotinib—EPHA6—nervous system—systemic lupus erythematosus	0.000351	0.00518	CbGeAlD
Nilotinib—HCK—lymphoid tissue—systemic lupus erythematosus	0.000348	0.00514	CbGeAlD
Nilotinib—BRAF—bone marrow—systemic lupus erythematosus	0.000348	0.00513	CbGeAlD
Nilotinib—MAP4K1—lung—systemic lupus erythematosus	0.000345	0.00509	CbGeAlD
Nilotinib—MAPK14—kidney—systemic lupus erythematosus	0.00034	0.00502	CbGeAlD
Nilotinib—MAPK8—central nervous system—systemic lupus erythematosus	0.000338	0.00499	CbGeAlD
Nilotinib—EPHA6—central nervous system—systemic lupus erythematosus	0.000338	0.00499	CbGeAlD
Nilotinib—TIE1—lung—systemic lupus erythematosus	0.000329	0.00485	CbGeAlD
Nilotinib—PDGFRA—connective tissue—systemic lupus erythematosus	0.000328	0.00484	CbGeAlD
Nilotinib—HCK—tendon—systemic lupus erythematosus	0.000327	0.00483	CbGeAlD
Nilotinib—ABL2—tendon—systemic lupus erythematosus	0.000325	0.0048	CbGeAlD
Nilotinib—LYN—nervous system—systemic lupus erythematosus	0.000324	0.00478	CbGeAlD
Nilotinib—EPHB4—kidney—systemic lupus erythematosus	0.000322	0.00475	CbGeAlD
Nilotinib—HCK—bone marrow—systemic lupus erythematosus	0.000317	0.00468	CbGeAlD
Nilotinib—BRAF—lung—systemic lupus erythematosus	0.000315	0.00465	CbGeAlD
Nilotinib—EPHB4—cortex of kidney—systemic lupus erythematosus	0.000314	0.00463	CbGeAlD
Nilotinib—EPHB3—lung—systemic lupus erythematosus	0.000313	0.00461	CbGeAlD
Nilotinib—EPHB6—skin of body—systemic lupus erythematosus	0.000312	0.00461	CbGeAlD
Nilotinib—LYN—central nervous system—systemic lupus erythematosus	0.000312	0.0046	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Methylprednisolone—systemic lupus erythematosus	0.000309	0.174	CbGdCrCtD
Nilotinib—TEK—kidney—systemic lupus erythematosus	0.000308	0.00455	CbGeAlD
Nilotinib—TIE1—nervous system—systemic lupus erythematosus	0.000304	0.00449	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Betamethasone—systemic lupus erythematosus	0.000304	0.172	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Dexamethasone—systemic lupus erythematosus	0.000304	0.172	CbGdCrCtD
Nilotinib—CA12—connective tissue—systemic lupus erythematosus	0.000303	0.00447	CbGeAlD
Nilotinib—TEK—cortex of kidney—systemic lupus erythematosus	0.0003	0.00443	CbGeAlD
Nilotinib—EPHA4—tendon—systemic lupus erythematosus	0.000298	0.00439	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Triamcinolone—systemic lupus erythematosus	0.000297	0.168	CbGdCrCtD
Nilotinib—CA3—tendon—systemic lupus erythematosus	0.000294	0.00434	CbGeAlD
Nilotinib—TIE1—central nervous system—systemic lupus erythematosus	0.000293	0.00433	CbGeAlD
Nilotinib—CA2—blood plasma—systemic lupus erythematosus	0.000292	0.00431	CbGeAlD
Nilotinib—MAPK14—lymphoid tissue—systemic lupus erythematosus	0.000292	0.00431	CbGeAlD
Nilotinib—FGR—lymphoid tissue—systemic lupus erythematosus	0.000291	0.00429	CbGeAlD
Nilotinib—EPHB3—nervous system—systemic lupus erythematosus	0.00029	0.00427	CbGeAlD
Nilotinib—CSF1R—connective tissue—systemic lupus erythematosus	0.000289	0.00426	CbGeAlD
Nilotinib—HCK—lung—systemic lupus erythematosus	0.000287	0.00424	CbGeAlD
Nilotinib—EPHB6—cortex of kidney—systemic lupus erythematosus	0.000287	0.00424	CbGeAlD
Nilotinib—ABL2—lung—systemic lupus erythematosus	0.000285	0.00421	CbGeAlD
Nilotinib—CA3—bone marrow—systemic lupus erythematosus	0.000285	0.0042	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisone—systemic lupus erythematosus	0.000282	0.159	CbGdCrCtD
Nilotinib—CA9—tendon—systemic lupus erythematosus	0.000281	0.00415	CbGeAlD
Nilotinib—EPHB3—central nervous system—systemic lupus erythematosus	0.000279	0.00411	CbGeAlD
Nilotinib—CYP2C8—blood plasma—systemic lupus erythematosus	0.000278	0.00411	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisolone—systemic lupus erythematosus	0.000275	0.155	CbGdCrCtD
Nilotinib—MAPK14—tendon—systemic lupus erythematosus	0.000274	0.00405	CbGeAlD
Nilotinib—FGR—tendon—systemic lupus erythematosus	0.000273	0.00403	CbGeAlD
Nilotinib—EPHA2—lymphoid tissue—systemic lupus erythematosus	0.000271	0.00401	CbGeAlD
Nilotinib—CA14—tendon—systemic lupus erythematosus	0.000267	0.00394	CbGeAlD
Nilotinib—UGT1A1—kidney—systemic lupus erythematosus	0.000266	0.00393	CbGeAlD
Nilotinib—HCK—nervous system—systemic lupus erythematosus	0.000266	0.00393	CbGeAlD
Nilotinib—MAPK14—bone marrow—systemic lupus erythematosus	0.000266	0.00392	CbGeAlD
Nilotinib—TEK—lymphoid tissue—systemic lupus erythematosus	0.000265	0.00391	CbGeAlD
Nilotinib—FGR—bone marrow—systemic lupus erythematosus	0.000265	0.00391	CbGeAlD
Nilotinib—LCK—bone marrow—systemic lupus erythematosus	0.000265	0.00391	CbGeAlD
Nilotinib—KIT—connective tissue—systemic lupus erythematosus	0.000262	0.00387	CbGeAlD
Nilotinib—EPHA4—lung—systemic lupus erythematosus	0.000261	0.00385	CbGeAlD
Nilotinib—CSF1R—skin of body—systemic lupus erythematosus	0.000261	0.00385	CbGeAlD
Nilotinib—EPHB4—tendon—systemic lupus erythematosus	0.00026	0.00384	CbGeAlD
Nilotinib—CA3—lung—systemic lupus erythematosus	0.000258	0.00381	CbGeAlD
Nilotinib—CA12—kidney—systemic lupus erythematosus	0.000258	0.00381	CbGeAlD
Nilotinib—PDGFRB—connective tissue—systemic lupus erythematosus	0.000256	0.00378	CbGeAlD
Nilotinib—HCK—central nervous system—systemic lupus erythematosus	0.000256	0.00378	CbGeAlD
Nilotinib—EPHA2—tendon—systemic lupus erythematosus	0.000255	0.00377	CbGeAlD
Nilotinib—KIT—nephron tubule—systemic lupus erythematosus	0.000254	0.00375	CbGeAlD
Nilotinib—EPHB4—bone marrow—systemic lupus erythematosus	0.000252	0.00372	CbGeAlD
Nilotinib—CYP2B6—blood plasma—systemic lupus erythematosus	0.000249	0.00368	CbGeAlD
Nilotinib—TEK—tendon—systemic lupus erythematosus	0.000249	0.00367	CbGeAlD
Nilotinib—CYP2C9—blood plasma—systemic lupus erythematosus	0.000247	0.00365	CbGeAlD
Nilotinib—MAP2K5—cortex of kidney—systemic lupus erythematosus	0.000245	0.00362	CbGeAlD
Nilotinib—EPHA4—nervous system—systemic lupus erythematosus	0.000242	0.00357	CbGeAlD
Nilotinib—MAPK14—lung—systemic lupus erythematosus	0.000241	0.00355	CbGeAlD
Nilotinib—PDGFRA—lymphoid tissue—systemic lupus erythematosus	0.00024	0.00354	CbGeAlD
Nilotinib—LCK—lung—systemic lupus erythematosus	0.00024	0.00354	CbGeAlD
Nilotinib—FGR—lung—systemic lupus erythematosus	0.00024	0.00354	CbGeAlD
Nilotinib—CA3—nervous system—systemic lupus erythematosus	0.000239	0.00353	CbGeAlD
Nilotinib—EPHB6—tendon—systemic lupus erythematosus	0.000238	0.00351	CbGeAlD
Nilotinib—KIT—skin of body—systemic lupus erythematosus	0.000237	0.0035	CbGeAlD
Nilotinib—EPHA4—central nervous system—systemic lupus erythematosus	0.000233	0.00344	CbGeAlD
Nilotinib—PDGFRB—skin of body—systemic lupus erythematosus	0.000231	0.00341	CbGeAlD
Nilotinib—CA3—central nervous system—systemic lupus erythematosus	0.00023	0.00339	CbGeAlD
Nilotinib—ABL1—connective tissue—systemic lupus erythematosus	0.000228	0.00337	CbGeAlD
Nilotinib—EPHB4—lung—systemic lupus erythematosus	0.000228	0.00337	CbGeAlD
Nilotinib—PDGFRA—tendon—systemic lupus erythematosus	0.000225	0.00333	CbGeAlD
Nilotinib—EPHA2—lung—systemic lupus erythematosus	0.000224	0.00331	CbGeAlD
Nilotinib—KIT—kidney—systemic lupus erythematosus	0.000223	0.0033	CbGeAlD
Nilotinib—MAPK14—nervous system—systemic lupus erythematosus	0.000223	0.00329	CbGeAlD
Nilotinib—FGR—nervous system—systemic lupus erythematosus	0.000222	0.00328	CbGeAlD
Nilotinib—ABL1—nephron tubule—systemic lupus erythematosus	0.000221	0.00326	CbGeAlD
Nilotinib—TEK—lung—systemic lupus erythematosus	0.000218	0.00322	CbGeAlD
Nilotinib—PDGFRB—kidney—systemic lupus erythematosus	0.000218	0.00322	CbGeAlD
Nilotinib—KIT—cortex of kidney—systemic lupus erythematosus	0.000217	0.00321	CbGeAlD
Nilotinib—MAPK14—central nervous system—systemic lupus erythematosus	0.000215	0.00317	CbGeAlD
Nilotinib—FGR—central nervous system—systemic lupus erythematosus	0.000214	0.00316	CbGeAlD
Nilotinib—PDGFRB—cortex of kidney—systemic lupus erythematosus	0.000212	0.00313	CbGeAlD
Nilotinib—CSF1R—lymphoid tissue—systemic lupus erythematosus	0.000211	0.00312	CbGeAlD
Nilotinib—EPHB6—lung—systemic lupus erythematosus	0.000209	0.00308	CbGeAlD
Nilotinib—EPHA2—nervous system—systemic lupus erythematosus	0.000207	0.00306	CbGeAlD
Nilotinib—ABL1—skin of body—systemic lupus erythematosus	0.000206	0.00304	CbGeAlD
Nilotinib—CA1—kidney—systemic lupus erythematosus	0.000204	0.00301	CbGeAlD
Nilotinib—MAP2K5—tendon—systemic lupus erythematosus	0.000203	0.003	CbGeAlD
Nilotinib—TEK—nervous system—systemic lupus erythematosus	0.000202	0.00299	CbGeAlD
Nilotinib—EPHA2—central nervous system—systemic lupus erythematosus	0.0002	0.00295	CbGeAlD
Nilotinib—CSF1R—tendon—systemic lupus erythematosus	0.000199	0.00293	CbGeAlD
Nilotinib—PDGFRA—lung—systemic lupus erythematosus	0.000198	0.00292	CbGeAlD
Nilotinib—TEK—central nervous system—systemic lupus erythematosus	0.000195	0.00287	CbGeAlD
Nilotinib—ABL1—kidney—systemic lupus erythematosus	0.000194	0.00287	CbGeAlD
Nilotinib—EPHB6—nervous system—systemic lupus erythematosus	0.000193	0.00285	CbGeAlD
Nilotinib—CSF1R—bone marrow—systemic lupus erythematosus	0.000192	0.00284	CbGeAlD
Nilotinib—KIT—lymphoid tissue—systemic lupus erythematosus	0.000192	0.00283	CbGeAlD
Nilotinib—ABL1—cortex of kidney—systemic lupus erythematosus	0.000189	0.00279	CbGeAlD
Nilotinib—CYP3A4—blood plasma—systemic lupus erythematosus	0.000188	0.00278	CbGeAlD
Nilotinib—PDGFRB—lymphoid tissue—systemic lupus erythematosus	0.000187	0.00276	CbGeAlD
Nilotinib—EPHB6—central nervous system—systemic lupus erythematosus	0.000186	0.00275	CbGeAlD
Nilotinib—CYP2D6—blood plasma—systemic lupus erythematosus	0.000185	0.00274	CbGeAlD
Nilotinib—PDGFRA—nervous system—systemic lupus erythematosus	0.000183	0.00271	CbGeAlD
Nilotinib—CA12—lung—systemic lupus erythematosus	0.000183	0.0027	CbGeAlD
Nilotinib—CA4—nephron tubule—systemic lupus erythematosus	0.000182	0.00268	CbGeAlD
Nilotinib—MAP2K5—lung—systemic lupus erythematosus	0.000179	0.00264	CbGeAlD
Nilotinib—PDGFRA—central nervous system—systemic lupus erythematosus	0.000176	0.0026	CbGeAlD
Nilotinib—PDGFRB—tendon—systemic lupus erythematosus	0.000176	0.0026	CbGeAlD
Nilotinib—CA1—lymphoid tissue—systemic lupus erythematosus	0.000175	0.00259	CbGeAlD
Nilotinib—KIT—bone marrow—systemic lupus erythematosus	0.000175	0.00258	CbGeAlD
Nilotinib—CSF1R—lung—systemic lupus erythematosus	0.000174	0.00257	CbGeAlD
Nilotinib—PDGFRB—bone marrow—systemic lupus erythematosus	0.000171	0.00252	CbGeAlD
Nilotinib—CA12—nervous system—systemic lupus erythematosus	0.000169	0.0025	CbGeAlD
Nilotinib—ABL1—lymphoid tissue—systemic lupus erythematosus	0.000167	0.00246	CbGeAlD
Nilotinib—MAP2K5—nervous system—systemic lupus erythematosus	0.000165	0.00244	CbGeAlD
Nilotinib—CA12—central nervous system—systemic lupus erythematosus	0.000163	0.0024	CbGeAlD
Nilotinib—CSF1R—nervous system—systemic lupus erythematosus	0.000161	0.00238	CbGeAlD
Nilotinib—CA1—bone marrow—systemic lupus erythematosus	0.00016	0.00236	CbGeAlD
Nilotinib—CA4—kidney—systemic lupus erythematosus	0.00016	0.00236	CbGeAlD
Nilotinib—MAP2K5—central nervous system—systemic lupus erythematosus	0.000159	0.00235	CbGeAlD
Nilotinib—KIT—lung—systemic lupus erythematosus	0.000158	0.00234	CbGeAlD
Nilotinib—ABL1—tendon—systemic lupus erythematosus	0.000157	0.00232	CbGeAlD
Nilotinib—CA2—connective tissue—systemic lupus erythematosus	0.000155	0.00229	CbGeAlD
Nilotinib—CA4—cortex of kidney—systemic lupus erythematosus	0.000155	0.00229	CbGeAlD
Nilotinib—CSF1R—central nervous system—systemic lupus erythematosus	0.000155	0.00229	CbGeAlD
Nilotinib—PDGFRB—lung—systemic lupus erythematosus	0.000155	0.00228	CbGeAlD
Nilotinib—Imatinib—ALB—systemic lupus erythematosus	0.000152	0.0481	CrCbGaD
Nilotinib—ABL1—bone marrow—systemic lupus erythematosus	0.000152	0.00224	CbGeAlD
Nilotinib—CA2—nephron tubule—systemic lupus erythematosus	0.000151	0.00222	CbGeAlD
Nilotinib—KIT—nervous system—systemic lupus erythematosus	0.000146	0.00216	CbGeAlD
Nilotinib—CA1—lung—systemic lupus erythematosus	0.000145	0.00214	CbGeAlD
Nilotinib—PDGFRB—nervous system—systemic lupus erythematosus	0.000143	0.00211	CbGeAlD
Nilotinib—KIT—central nervous system—systemic lupus erythematosus	0.000141	0.00208	CbGeAlD
Nilotinib—CA2—skin of body—systemic lupus erythematosus	0.00014	0.00207	CbGeAlD
Nilotinib—ABCG2—nephron tubule—systemic lupus erythematosus	0.000139	0.00206	CbGeAlD
Nilotinib—PDGFRB—central nervous system—systemic lupus erythematosus	0.000138	0.00203	CbGeAlD
Nilotinib—ABL1—lung—systemic lupus erythematosus	0.000138	0.00203	CbGeAlD
Nilotinib—CA1—nervous system—systemic lupus erythematosus	0.000134	0.00198	CbGeAlD
Nilotinib—ABCB1—blood plasma—systemic lupus erythematosus	0.000133	0.00197	CbGeAlD
Nilotinib—CA2—kidney—systemic lupus erythematosus	0.000132	0.00195	CbGeAlD
Nilotinib—CA1—central nervous system—systemic lupus erythematosus	0.000129	0.0019	CbGeAlD
Nilotinib—CA2—cortex of kidney—systemic lupus erythematosus	0.000129	0.0019	CbGeAlD
Nilotinib—CA4—tendon—systemic lupus erythematosus	0.000129	0.0019	CbGeAlD
Nilotinib—CYP2B6—nephron tubule—systemic lupus erythematosus	0.000129	0.0019	CbGeAlD
Nilotinib—ABL1—nervous system—systemic lupus erythematosus	0.000128	0.00188	CbGeAlD
Nilotinib—CYP2C8—kidney—systemic lupus erythematosus	0.000126	0.00186	CbGeAlD
Nilotinib—CA4—bone marrow—systemic lupus erythematosus	0.000125	0.00184	CbGeAlD
Nilotinib—ABL1—central nervous system—systemic lupus erythematosus	0.000123	0.00181	CbGeAlD
Nilotinib—CYP2B6—skin of body—systemic lupus erythematosus	0.00012	0.00177	CbGeAlD
Nilotinib—CA2—lymphoid tissue—systemic lupus erythematosus	0.000114	0.00168	CbGeAlD
Nilotinib—CA4—lung—systemic lupus erythematosus	0.000113	0.00167	CbGeAlD
Nilotinib—CYP2B6—kidney—systemic lupus erythematosus	0.000113	0.00167	CbGeAlD
Nilotinib—CA2—tendon—systemic lupus erythematosus	0.000107	0.00158	CbGeAlD
Nilotinib—CA4—nervous system—systemic lupus erythematosus	0.000105	0.00155	CbGeAlD
Nilotinib—CA2—bone marrow—systemic lupus erythematosus	0.000104	0.00153	CbGeAlD
Nilotinib—CA4—central nervous system—systemic lupus erythematosus	0.000101	0.00149	CbGeAlD
Nilotinib—CYP2B6—lymphoid tissue—systemic lupus erythematosus	9.71e-05	0.00143	CbGeAlD
Nilotinib—ABCG2—bone marrow—systemic lupus erythematosus	9.59e-05	0.00142	CbGeAlD
Nilotinib—CA2—lung—systemic lupus erythematosus	9.38e-05	0.00138	CbGeAlD
Nilotinib—ABCG2—lung—systemic lupus erythematosus	8.68e-05	0.00128	CbGeAlD
Nilotinib—CA2—nervous system—systemic lupus erythematosus	8.68e-05	0.00128	CbGeAlD
Nilotinib—CYP3A4—kidney—systemic lupus erythematosus	8.54e-05	0.00126	CbGeAlD
Nilotinib—CYP2D6—kidney—systemic lupus erythematosus	8.4e-05	0.00124	CbGeAlD
Nilotinib—CA2—central nervous system—systemic lupus erythematosus	8.36e-05	0.00123	CbGeAlD
Nilotinib—CYP2B6—lung—systemic lupus erythematosus	8.01e-05	0.00118	CbGeAlD
Nilotinib—CYP2B6—nervous system—systemic lupus erythematosus	7.42e-05	0.0011	CbGeAlD
Nilotinib—CYP2B6—central nervous system—systemic lupus erythematosus	7.14e-05	0.00105	CbGeAlD
Nilotinib—ABCB1—nephron tubule—systemic lupus erythematosus	6.88e-05	0.00102	CbGeAlD
Nilotinib—ABCB1—kidney—systemic lupus erythematosus	6.04e-05	0.000892	CbGeAlD
Nilotinib—ABCB1—cortex of kidney—systemic lupus erythematosus	5.89e-05	0.000869	CbGeAlD
Nilotinib—CYP3A4—nervous system—systemic lupus erythematosus	5.6e-05	0.000827	CbGeAlD
Nilotinib—CYP2D6—nervous system—systemic lupus erythematosus	5.51e-05	0.000814	CbGeAlD
Nilotinib—CYP3A4—central nervous system—systemic lupus erythematosus	5.39e-05	0.000796	CbGeAlD
Nilotinib—CYP2D6—central nervous system—systemic lupus erythematosus	5.31e-05	0.000784	CbGeAlD
Nilotinib—ABCB1—lymphoid tissue—systemic lupus erythematosus	5.19e-05	0.000766	CbGeAlD
Nilotinib—ABCB1—bone marrow—systemic lupus erythematosus	4.73e-05	0.000698	CbGeAlD
Nilotinib—ABCB1—lung—systemic lupus erythematosus	4.28e-05	0.000632	CbGeAlD
Nilotinib—ABCB1—nervous system—systemic lupus erythematosus	3.97e-05	0.000585	CbGeAlD
Nilotinib—ABCB1—central nervous system—systemic lupus erythematosus	3.82e-05	0.000564	CbGeAlD
Nilotinib—Urinary tract disorder—Methotrexate—systemic lupus erythematosus	3.54e-05	0.0003	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	3.54e-05	0.0003	CcSEcCtD
Nilotinib—Fatigue—Hydrocortisone—systemic lupus erythematosus	3.53e-05	0.0003	CcSEcCtD
Nilotinib—Vision blurred—Prednisone—systemic lupus erythematosus	3.52e-05	0.000299	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—systemic lupus erythematosus	3.52e-05	0.000298	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	3.52e-05	0.000298	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	3.51e-05	0.000297	CcSEcCtD
Nilotinib—Pain—Hydrocortisone—systemic lupus erythematosus	3.5e-05	0.000297	CcSEcCtD
Nilotinib—Oedema—Dexamethasone—systemic lupus erythematosus	3.5e-05	0.000297	CcSEcCtD
Nilotinib—Oedema—Betamethasone—systemic lupus erythematosus	3.5e-05	0.000297	CcSEcCtD
Nilotinib—Insomnia—Triamcinolone—systemic lupus erythematosus	3.49e-05	0.000296	CcSEcCtD
Nilotinib—Insomnia—Methylprednisolone—systemic lupus erythematosus	3.48e-05	0.000295	CcSEcCtD
Nilotinib—Infection—Betamethasone—systemic lupus erythematosus	3.48e-05	0.000295	CcSEcCtD
Nilotinib—Infection—Dexamethasone—systemic lupus erythematosus	3.48e-05	0.000295	CcSEcCtD
Nilotinib—Ill-defined disorder—Prednisone—systemic lupus erythematosus	3.47e-05	0.000294	CcSEcCtD
Nilotinib—Paraesthesia—Triamcinolone—systemic lupus erythematosus	3.46e-05	0.000294	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisolone—systemic lupus erythematosus	3.46e-05	0.000293	CcSEcCtD
Nilotinib—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	3.46e-05	0.000293	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—systemic lupus erythematosus	3.46e-05	0.000293	CcSEcCtD
Nilotinib—Anaemia—Prednisone—systemic lupus erythematosus	3.45e-05	0.000293	CcSEcCtD
Nilotinib—Shock—Betamethasone—systemic lupus erythematosus	3.44e-05	0.000292	CcSEcCtD
Nilotinib—Shock—Dexamethasone—systemic lupus erythematosus	3.44e-05	0.000292	CcSEcCtD
Nilotinib—Dyspnoea—Triamcinolone—systemic lupus erythematosus	3.44e-05	0.000292	CcSEcCtD
Nilotinib—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	3.43e-05	0.000291	CcSEcCtD
Nilotinib—Nervous system disorder—Betamethasone—systemic lupus erythematosus	3.43e-05	0.000291	CcSEcCtD
Nilotinib—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	3.43e-05	0.000291	CcSEcCtD
Nilotinib—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	3.43e-05	0.000291	CcSEcCtD
Nilotinib—Tachycardia—Dexamethasone—systemic lupus erythematosus	3.42e-05	0.00029	CcSEcCtD
Nilotinib—Tachycardia—Betamethasone—systemic lupus erythematosus	3.42e-05	0.00029	CcSEcCtD
Nilotinib—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	3.4e-05	0.000288	CcSEcCtD
Nilotinib—Dyspepsia—Triamcinolone—systemic lupus erythematosus	3.4e-05	0.000288	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—systemic lupus erythematosus	3.39e-05	0.000288	CcSEcCtD
Nilotinib—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	3.39e-05	0.000287	CcSEcCtD
Nilotinib—Hyperhidrosis—Betamethasone—systemic lupus erythematosus	3.38e-05	0.000287	CcSEcCtD
Nilotinib—Hyperhidrosis—Dexamethasone—systemic lupus erythematosus	3.38e-05	0.000287	CcSEcCtD
Nilotinib—Feeling abnormal—Hydrocortisone—systemic lupus erythematosus	3.38e-05	0.000286	CcSEcCtD
Nilotinib—Malaise—Prednisone—systemic lupus erythematosus	3.37e-05	0.000286	CcSEcCtD
Nilotinib—Vertigo—Prednisone—systemic lupus erythematosus	3.36e-05	0.000285	CcSEcCtD
Nilotinib—Eye disorder—Methotrexate—systemic lupus erythematosus	3.35e-05	0.000284	CcSEcCtD
Nilotinib—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	3.35e-05	0.000284	CcSEcCtD
Nilotinib—Syncope—Prednisone—systemic lupus erythematosus	3.35e-05	0.000284	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—systemic lupus erythematosus	3.34e-05	0.000284	CcSEcCtD
Nilotinib—Anorexia—Dexamethasone—systemic lupus erythematosus	3.34e-05	0.000283	CcSEcCtD
Nilotinib—Anorexia—Betamethasone—systemic lupus erythematosus	3.34e-05	0.000283	CcSEcCtD
Nilotinib—Urticaria—Prednisolone—systemic lupus erythematosus	3.33e-05	0.000283	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—systemic lupus erythematosus	3.33e-05	0.000282	CcSEcCtD
Nilotinib—Fatigue—Triamcinolone—systemic lupus erythematosus	3.33e-05	0.000282	CcSEcCtD
Nilotinib—Fatigue—Methylprednisolone—systemic lupus erythematosus	3.32e-05	0.000281	CcSEcCtD
Nilotinib—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	3.31e-05	0.000281	CcSEcCtD
Nilotinib—Asthenia—Cyclosporine—systemic lupus erythematosus	3.31e-05	0.000281	CcSEcCtD
Nilotinib—Pain—Triamcinolone—systemic lupus erythematosus	3.3e-05	0.00028	CcSEcCtD
Nilotinib—Loss of consciousness—Prednisone—systemic lupus erythematosus	3.28e-05	0.000278	CcSEcCtD
Nilotinib—Hypotension—Betamethasone—systemic lupus erythematosus	3.27e-05	0.000277	CcSEcCtD
Nilotinib—Hypotension—Dexamethasone—systemic lupus erythematosus	3.27e-05	0.000277	CcSEcCtD
Nilotinib—Pruritus—Cyclosporine—systemic lupus erythematosus	3.26e-05	0.000277	CcSEcCtD
Nilotinib—Urticaria—Hydrocortisone—systemic lupus erythematosus	3.26e-05	0.000276	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—systemic lupus erythematosus	3.25e-05	0.000276	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—systemic lupus erythematosus	3.24e-05	0.000275	CcSEcCtD
Nilotinib—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	3.24e-05	0.000275	CcSEcCtD
Nilotinib—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	3.24e-05	0.000275	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	3.23e-05	0.000274	CcSEcCtD
Nilotinib—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	3.23e-05	0.000274	CcSEcCtD
Nilotinib—Hypertension—Prednisone—systemic lupus erythematosus	3.23e-05	0.000274	CcSEcCtD
Nilotinib—Chills—Methotrexate—systemic lupus erythematosus	3.22e-05	0.000273	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	3.19e-05	0.000271	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	3.19e-05	0.000271	CcSEcCtD
Nilotinib—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	3.18e-05	0.00027	CcSEcCtD
Nilotinib—Arthralgia—Prednisone—systemic lupus erythematosus	3.18e-05	0.00027	CcSEcCtD
Nilotinib—Myalgia—Prednisone—systemic lupus erythematosus	3.18e-05	0.00027	CcSEcCtD
Nilotinib—Feeling abnormal—Triamcinolone—systemic lupus erythematosus	3.18e-05	0.00027	CcSEcCtD
Nilotinib—Feeling abnormal—Methylprednisolone—systemic lupus erythematosus	3.17e-05	0.000269	CcSEcCtD
Nilotinib—Anxiety—Prednisone—systemic lupus erythematosus	3.17e-05	0.000269	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—systemic lupus erythematosus	3.17e-05	0.000269	CcSEcCtD
Nilotinib—Insomnia—Dexamethasone—systemic lupus erythematosus	3.17e-05	0.000269	CcSEcCtD
Nilotinib—Insomnia—Betamethasone—systemic lupus erythematosus	3.17e-05	0.000269	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	3.16e-05	0.000268	CcSEcCtD
Nilotinib—Diarrhoea—Cyclosporine—systemic lupus erythematosus	3.15e-05	0.000268	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	3.15e-05	0.000267	CcSEcCtD
Nilotinib—Paraesthesia—Betamethasone—systemic lupus erythematosus	3.14e-05	0.000267	CcSEcCtD
Nilotinib—Paraesthesia—Dexamethasone—systemic lupus erythematosus	3.14e-05	0.000267	CcSEcCtD
Nilotinib—Discomfort—Prednisone—systemic lupus erythematosus	3.14e-05	0.000266	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—systemic lupus erythematosus	3.14e-05	0.000266	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—systemic lupus erythematosus	3.12e-05	0.000265	CcSEcCtD
Nilotinib—Erythema—Methotrexate—systemic lupus erythematosus	3.12e-05	0.000265	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisolone—systemic lupus erythematosus	3.09e-05	0.000262	CcSEcCtD
Nilotinib—Dyspepsia—Dexamethasone—systemic lupus erythematosus	3.08e-05	0.000261	CcSEcCtD
Nilotinib—Dyspepsia—Betamethasone—systemic lupus erythematosus	3.08e-05	0.000261	CcSEcCtD
Nilotinib—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	3.08e-05	0.000261	CcSEcCtD
Nilotinib—Urticaria—Triamcinolone—systemic lupus erythematosus	3.07e-05	0.00026	CcSEcCtD
Nilotinib—Urticaria—Methylprednisolone—systemic lupus erythematosus	3.06e-05	0.000259	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—systemic lupus erythematosus	3.06e-05	0.000259	CcSEcCtD
Nilotinib—Body temperature increased—Triamcinolone—systemic lupus erythematosus	3.05e-05	0.000259	CcSEcCtD
Nilotinib—Dizziness—Cyclosporine—systemic lupus erythematosus	3.05e-05	0.000259	CcSEcCtD
Nilotinib—Oedema—Prednisone—systemic lupus erythematosus	3.05e-05	0.000259	CcSEcCtD
Nilotinib—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	3.04e-05	0.000258	CcSEcCtD
Nilotinib—Decreased appetite—Dexamethasone—systemic lupus erythematosus	3.04e-05	0.000258	CcSEcCtD
Nilotinib—Decreased appetite—Betamethasone—systemic lupus erythematosus	3.04e-05	0.000258	CcSEcCtD
Nilotinib—Infection—Prednisone—systemic lupus erythematosus	3.03e-05	0.000257	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	3.02e-05	0.000256	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	3.02e-05	0.000256	CcSEcCtD
Nilotinib—Back pain—Methotrexate—systemic lupus erythematosus	3.02e-05	0.000256	CcSEcCtD
Nilotinib—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	3.02e-05	0.000256	CcSEcCtD
Nilotinib—Fatigue—Dexamethasone—systemic lupus erythematosus	3.02e-05	0.000256	CcSEcCtD
Nilotinib—Fatigue—Betamethasone—systemic lupus erythematosus	3.02e-05	0.000256	CcSEcCtD
Nilotinib—Shock—Prednisone—systemic lupus erythematosus	3e-05	0.000254	CcSEcCtD
Nilotinib—Pain—Dexamethasone—systemic lupus erythematosus	2.99e-05	0.000254	CcSEcCtD
Nilotinib—Pain—Betamethasone—systemic lupus erythematosus	2.99e-05	0.000254	CcSEcCtD
Nilotinib—Nervous system disorder—Prednisone—systemic lupus erythematosus	2.99e-05	0.000254	CcSEcCtD
Nilotinib—Tachycardia—Prednisone—systemic lupus erythematosus	2.98e-05	0.000252	CcSEcCtD
Nilotinib—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	2.97e-05	0.000252	CcSEcCtD
Nilotinib—Skin disorder—Prednisone—systemic lupus erythematosus	2.96e-05	0.000251	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisone—systemic lupus erythematosus	2.95e-05	0.00025	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—systemic lupus erythematosus	2.94e-05	0.00025	CcSEcCtD
Nilotinib—Asthenia—Hydrocortisone—systemic lupus erythematosus	2.94e-05	0.000249	CcSEcCtD
Nilotinib—Vomiting—Cyclosporine—systemic lupus erythematosus	2.93e-05	0.000249	CcSEcCtD
Nilotinib—Rash—Cyclosporine—systemic lupus erythematosus	2.91e-05	0.000247	CcSEcCtD
Nilotinib—Anorexia—Prednisone—systemic lupus erythematosus	2.91e-05	0.000246	CcSEcCtD
Nilotinib—Dermatitis—Cyclosporine—systemic lupus erythematosus	2.9e-05	0.000246	CcSEcCtD
Nilotinib—Pruritus—Hydrocortisone—systemic lupus erythematosus	2.9e-05	0.000246	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—systemic lupus erythematosus	2.9e-05	0.000246	CcSEcCtD
Nilotinib—Headache—Cyclosporine—systemic lupus erythematosus	2.89e-05	0.000245	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—systemic lupus erythematosus	2.89e-05	0.000245	CcSEcCtD
Nilotinib—Feeling abnormal—Betamethasone—systemic lupus erythematosus	2.89e-05	0.000245	CcSEcCtD
Nilotinib—Feeling abnormal—Dexamethasone—systemic lupus erythematosus	2.89e-05	0.000245	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	2.86e-05	0.000243	CcSEcCtD
Nilotinib—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	2.86e-05	0.000243	CcSEcCtD
Nilotinib—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	2.86e-05	0.000243	CcSEcCtD
Nilotinib—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	2.84e-05	0.000241	CcSEcCtD
Nilotinib—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	2.84e-05	0.000241	CcSEcCtD
Nilotinib—Rash—Mycophenolate mofetil—systemic lupus erythematosus	2.84e-05	0.000241	CcSEcCtD
Nilotinib—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	2.83e-05	0.00024	CcSEcCtD
Nilotinib—Headache—Mycophenolate mofetil—systemic lupus erythematosus	2.82e-05	0.000239	CcSEcCtD
Nilotinib—Malaise—Methotrexate—systemic lupus erythematosus	2.82e-05	0.000239	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—systemic lupus erythematosus	2.81e-05	0.000238	CcSEcCtD
Nilotinib—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	2.8e-05	0.000238	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—systemic lupus erythematosus	2.79e-05	0.000237	CcSEcCtD
Nilotinib—Urticaria—Dexamethasone—systemic lupus erythematosus	2.78e-05	0.000236	CcSEcCtD
Nilotinib—Urticaria—Betamethasone—systemic lupus erythematosus	2.78e-05	0.000236	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	2.78e-05	0.000236	CcSEcCtD
Nilotinib—Dizziness—Prednisolone—systemic lupus erythematosus	2.77e-05	0.000235	CcSEcCtD
Nilotinib—Asthenia—Triamcinolone—systemic lupus erythematosus	2.77e-05	0.000235	CcSEcCtD
Nilotinib—Body temperature increased—Betamethasone—systemic lupus erythematosus	2.77e-05	0.000235	CcSEcCtD
Nilotinib—Abdominal pain—Betamethasone—systemic lupus erythematosus	2.77e-05	0.000235	CcSEcCtD
Nilotinib—Abdominal pain—Dexamethasone—systemic lupus erythematosus	2.77e-05	0.000235	CcSEcCtD
Nilotinib—Body temperature increased—Dexamethasone—systemic lupus erythematosus	2.77e-05	0.000235	CcSEcCtD
Nilotinib—Asthenia—Methylprednisolone—systemic lupus erythematosus	2.76e-05	0.000234	CcSEcCtD
Nilotinib—Insomnia—Prednisone—systemic lupus erythematosus	2.76e-05	0.000234	CcSEcCtD
Nilotinib—Nausea—Cyclosporine—systemic lupus erythematosus	2.74e-05	0.000232	CcSEcCtD
Nilotinib—Paraesthesia—Prednisone—systemic lupus erythematosus	2.74e-05	0.000232	CcSEcCtD
Nilotinib—Pruritus—Triamcinolone—systemic lupus erythematosus	2.73e-05	0.000232	CcSEcCtD
Nilotinib—Cough—Methotrexate—systemic lupus erythematosus	2.72e-05	0.000231	CcSEcCtD
Nilotinib—Pruritus—Methylprednisolone—systemic lupus erythematosus	2.72e-05	0.000231	CcSEcCtD
Nilotinib—Dizziness—Hydrocortisone—systemic lupus erythematosus	2.71e-05	0.00023	CcSEcCtD
Nilotinib—Dyspepsia—Prednisone—systemic lupus erythematosus	2.68e-05	0.000228	CcSEcCtD
Nilotinib—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	2.67e-05	0.000227	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—systemic lupus erythematosus	2.66e-05	0.000225	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—systemic lupus erythematosus	2.66e-05	0.000225	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—systemic lupus erythematosus	2.66e-05	0.000225	CcSEcCtD
Nilotinib—Decreased appetite—Prednisone—systemic lupus erythematosus	2.65e-05	0.000225	CcSEcCtD
Nilotinib—Rash—Prednisolone—systemic lupus erythematosus	2.65e-05	0.000224	CcSEcCtD
Nilotinib—Dermatitis—Prednisolone—systemic lupus erythematosus	2.64e-05	0.000224	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	2.64e-05	0.000224	CcSEcCtD
Nilotinib—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	2.63e-05	0.000223	CcSEcCtD
Nilotinib—Fatigue—Prednisone—systemic lupus erythematosus	2.63e-05	0.000223	CcSEcCtD
Nilotinib—Headache—Prednisolone—systemic lupus erythematosus	2.63e-05	0.000223	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—systemic lupus erythematosus	2.63e-05	0.000223	CcSEcCtD
Nilotinib—Constipation—Prednisone—systemic lupus erythematosus	2.61e-05	0.000221	CcSEcCtD
Nilotinib—Vomiting—Hydrocortisone—systemic lupus erythematosus	2.61e-05	0.000221	CcSEcCtD
Nilotinib—Rash—Hydrocortisone—systemic lupus erythematosus	2.58e-05	0.000219	CcSEcCtD
Nilotinib—Dermatitis—Hydrocortisone—systemic lupus erythematosus	2.58e-05	0.000219	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—systemic lupus erythematosus	2.57e-05	0.000218	CcSEcCtD
Nilotinib—Headache—Hydrocortisone—systemic lupus erythematosus	2.57e-05	0.000218	CcSEcCtD
Nilotinib—Dizziness—Triamcinolone—systemic lupus erythematosus	2.55e-05	0.000216	CcSEcCtD
Nilotinib—Dizziness—Methylprednisolone—systemic lupus erythematosus	2.55e-05	0.000216	CcSEcCtD
Nilotinib—Infection—Methotrexate—systemic lupus erythematosus	2.53e-05	0.000215	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisone—systemic lupus erythematosus	2.51e-05	0.000213	CcSEcCtD
Nilotinib—Asthenia—Betamethasone—systemic lupus erythematosus	2.51e-05	0.000213	CcSEcCtD
Nilotinib—Asthenia—Dexamethasone—systemic lupus erythematosus	2.51e-05	0.000213	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—systemic lupus erythematosus	2.5e-05	0.000212	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	2.49e-05	0.000212	CcSEcCtD
Nilotinib—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	2.49e-05	0.000211	CcSEcCtD
Nilotinib—Nausea—Prednisolone—systemic lupus erythematosus	2.49e-05	0.000211	CcSEcCtD
Nilotinib—Pruritus—Betamethasone—systemic lupus erythematosus	2.48e-05	0.00021	CcSEcCtD
Nilotinib—Pruritus—Dexamethasone—systemic lupus erythematosus	2.48e-05	0.00021	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—systemic lupus erythematosus	2.48e-05	0.00021	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—systemic lupus erythematosus	2.46e-05	0.000209	CcSEcCtD
Nilotinib—Vomiting—Triamcinolone—systemic lupus erythematosus	2.45e-05	0.000208	CcSEcCtD
Nilotinib—Vomiting—Methylprednisolone—systemic lupus erythematosus	2.45e-05	0.000208	CcSEcCtD
Nilotinib—Nausea—Hydrocortisone—systemic lupus erythematosus	2.43e-05	0.000206	CcSEcCtD
Nilotinib—Rash—Triamcinolone—systemic lupus erythematosus	2.43e-05	0.000206	CcSEcCtD
Nilotinib—Dermatitis—Triamcinolone—systemic lupus erythematosus	2.43e-05	0.000206	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—systemic lupus erythematosus	2.43e-05	0.000206	CcSEcCtD
Nilotinib—Rash—Methylprednisolone—systemic lupus erythematosus	2.43e-05	0.000206	CcSEcCtD
Nilotinib—Dermatitis—Methylprednisolone—systemic lupus erythematosus	2.43e-05	0.000206	CcSEcCtD
Nilotinib—Urticaria—Prednisone—systemic lupus erythematosus	2.42e-05	0.000205	CcSEcCtD
Nilotinib—Headache—Triamcinolone—systemic lupus erythematosus	2.42e-05	0.000205	CcSEcCtD
Nilotinib—Headache—Methylprednisolone—systemic lupus erythematosus	2.41e-05	0.000205	CcSEcCtD
Nilotinib—Abdominal pain—Prednisone—systemic lupus erythematosus	2.41e-05	0.000204	CcSEcCtD
Nilotinib—Body temperature increased—Prednisone—systemic lupus erythematosus	2.41e-05	0.000204	CcSEcCtD
Nilotinib—Diarrhoea—Dexamethasone—systemic lupus erythematosus	2.4e-05	0.000203	CcSEcCtD
Nilotinib—Diarrhoea—Betamethasone—systemic lupus erythematosus	2.4e-05	0.000203	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—systemic lupus erythematosus	2.38e-05	0.000202	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	2.32e-05	0.000197	CcSEcCtD
Nilotinib—Dizziness—Dexamethasone—systemic lupus erythematosus	2.32e-05	0.000196	CcSEcCtD
Nilotinib—Dizziness—Betamethasone—systemic lupus erythematosus	2.32e-05	0.000196	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—systemic lupus erythematosus	2.3e-05	0.000195	CcSEcCtD
Nilotinib—Nausea—Triamcinolone—systemic lupus erythematosus	2.29e-05	0.000194	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—systemic lupus erythematosus	2.29e-05	0.000194	CcSEcCtD
Nilotinib—Nausea—Methylprednisolone—systemic lupus erythematosus	2.29e-05	0.000194	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—systemic lupus erythematosus	2.27e-05	0.000193	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisone—systemic lupus erythematosus	2.25e-05	0.000191	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—systemic lupus erythematosus	2.24e-05	0.00019	CcSEcCtD
Nilotinib—Vomiting—Dexamethasone—systemic lupus erythematosus	2.23e-05	0.000189	CcSEcCtD
Nilotinib—Vomiting—Betamethasone—systemic lupus erythematosus	2.23e-05	0.000189	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—systemic lupus erythematosus	2.22e-05	0.000188	CcSEcCtD
Nilotinib—Rash—Betamethasone—systemic lupus erythematosus	2.21e-05	0.000187	CcSEcCtD
Nilotinib—Rash—Dexamethasone—systemic lupus erythematosus	2.21e-05	0.000187	CcSEcCtD
Nilotinib—Dermatitis—Betamethasone—systemic lupus erythematosus	2.21e-05	0.000187	CcSEcCtD
Nilotinib—Dermatitis—Dexamethasone—systemic lupus erythematosus	2.21e-05	0.000187	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	2.2e-05	0.000187	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—systemic lupus erythematosus	2.2e-05	0.000186	CcSEcCtD
Nilotinib—Headache—Betamethasone—systemic lupus erythematosus	2.19e-05	0.000186	CcSEcCtD
Nilotinib—Headache—Dexamethasone—systemic lupus erythematosus	2.19e-05	0.000186	CcSEcCtD
Nilotinib—Asthenia—Prednisone—systemic lupus erythematosus	2.19e-05	0.000186	CcSEcCtD
Nilotinib—Pain—Methotrexate—systemic lupus erythematosus	2.18e-05	0.000185	CcSEcCtD
Nilotinib—Pruritus—Prednisone—systemic lupus erythematosus	2.16e-05	0.000183	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—systemic lupus erythematosus	2.1e-05	0.000178	CcSEcCtD
Nilotinib—Diarrhoea—Prednisone—systemic lupus erythematosus	2.09e-05	0.000177	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	2.08e-05	0.000177	CcSEcCtD
Nilotinib—Nausea—Dexamethasone—systemic lupus erythematosus	2.08e-05	0.000176	CcSEcCtD
Nilotinib—Nausea—Betamethasone—systemic lupus erythematosus	2.08e-05	0.000176	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—systemic lupus erythematosus	2.02e-05	0.000172	CcSEcCtD
Nilotinib—Dizziness—Prednisone—systemic lupus erythematosus	2.02e-05	0.000171	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—systemic lupus erythematosus	2.01e-05	0.000171	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—systemic lupus erythematosus	2.01e-05	0.000171	CcSEcCtD
Nilotinib—Vomiting—Prednisone—systemic lupus erythematosus	1.94e-05	0.000164	CcSEcCtD
Nilotinib—Rash—Prednisone—systemic lupus erythematosus	1.92e-05	0.000163	CcSEcCtD
Nilotinib—Dermatitis—Prednisone—systemic lupus erythematosus	1.92e-05	0.000163	CcSEcCtD
Nilotinib—Headache—Prednisone—systemic lupus erythematosus	1.91e-05	0.000162	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—systemic lupus erythematosus	1.88e-05	0.000159	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—systemic lupus erythematosus	1.83e-05	0.000155	CcSEcCtD
Nilotinib—Nausea—Prednisone—systemic lupus erythematosus	1.81e-05	0.000154	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—systemic lupus erythematosus	1.8e-05	0.000153	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—systemic lupus erythematosus	1.74e-05	0.000148	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—systemic lupus erythematosus	1.69e-05	0.000143	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—systemic lupus erythematosus	1.62e-05	0.000137	CcSEcCtD
Nilotinib—Rash—Methotrexate—systemic lupus erythematosus	1.61e-05	0.000136	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—systemic lupus erythematosus	1.61e-05	0.000136	CcSEcCtD
Nilotinib—Headache—Methotrexate—systemic lupus erythematosus	1.6e-05	0.000135	CcSEcCtD
Nilotinib—Nausea—Methotrexate—systemic lupus erythematosus	1.51e-05	0.000128	CcSEcCtD
Nilotinib—PDGFRA—Signaling Pathways—F2—systemic lupus erythematosus	1.68e-06	1.3e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—systemic lupus erythematosus	1.67e-06	1.3e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—systemic lupus erythematosus	1.67e-06	1.3e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—systemic lupus erythematosus	1.67e-06	1.3e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—systemic lupus erythematosus	1.67e-06	1.3e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL2—systemic lupus erythematosus	1.66e-06	1.29e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD80—systemic lupus erythematosus	1.66e-06	1.29e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—EP300—systemic lupus erythematosus	1.66e-06	1.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CDKN1B—systemic lupus erythematosus	1.65e-06	1.28e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CDKN1A—systemic lupus erythematosus	1.65e-06	1.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IFNG—systemic lupus erythematosus	1.64e-06	1.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCR5—systemic lupus erythematosus	1.63e-06	1.27e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1.63e-06	1.26e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CDKN1B—systemic lupus erythematosus	1.61e-06	1.25e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2RA—systemic lupus erythematosus	1.61e-06	1.25e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CDKN1B—systemic lupus erythematosus	1.61e-06	1.25e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CD80—systemic lupus erythematosus	1.61e-06	1.25e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CDKN1A—systemic lupus erythematosus	1.61e-06	1.25e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—C3—systemic lupus erythematosus	1.6e-06	1.24e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TYK2—systemic lupus erythematosus	1.59e-06	1.24e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—systemic lupus erythematosus	1.59e-06	1.24e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—systemic lupus erythematosus	1.59e-06	1.23e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—systemic lupus erythematosus	1.58e-06	1.23e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCL2—systemic lupus erythematosus	1.58e-06	1.23e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL2—systemic lupus erythematosus	1.58e-06	1.23e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TYK2—systemic lupus erythematosus	1.57e-06	1.22e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CDKN1B—systemic lupus erythematosus	1.57e-06	1.22e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—systemic lupus erythematosus	1.57e-06	1.22e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—systemic lupus erythematosus	1.57e-06	1.22e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTGS2—systemic lupus erythematosus	1.57e-06	1.22e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EP300—systemic lupus erythematosus	1.57e-06	1.22e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CDKN1B—systemic lupus erythematosus	1.57e-06	1.22e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CDKN1A—systemic lupus erythematosus	1.57e-06	1.22e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NOS3—systemic lupus erythematosus	1.56e-06	1.21e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—systemic lupus erythematosus	1.55e-06	1.21e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—systemic lupus erythematosus	1.55e-06	1.2e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NOS3—systemic lupus erythematosus	1.55e-06	1.2e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—systemic lupus erythematosus	1.54e-06	1.2e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—systemic lupus erythematosus	1.54e-06	1.2e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—systemic lupus erythematosus	1.53e-06	1.19e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PPARG—systemic lupus erythematosus	1.53e-06	1.19e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—EP300—systemic lupus erythematosus	1.53e-06	1.19e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CDKN1A—systemic lupus erythematosus	1.52e-06	1.18e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—TYK2—systemic lupus erythematosus	1.52e-06	1.18e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—F2—systemic lupus erythematosus	1.51e-06	1.17e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—systemic lupus erythematosus	1.51e-06	1.17e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—systemic lupus erythematosus	1.51e-06	1.17e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—RXRA—systemic lupus erythematosus	1.51e-06	1.17e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—systemic lupus erythematosus	1.5e-06	1.17e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCL2—systemic lupus erythematosus	1.49e-06	1.16e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—systemic lupus erythematosus	1.49e-06	1.16e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CDKN1B—systemic lupus erythematosus	1.49e-06	1.16e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JAK1—systemic lupus erythematosus	1.49e-06	1.16e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EP300—systemic lupus erythematosus	1.49e-06	1.16e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CDKN1A—systemic lupus erythematosus	1.49e-06	1.16e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CDKN1B—systemic lupus erythematosus	1.48e-06	1.15e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CDKN1A—systemic lupus erythematosus	1.48e-06	1.15e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—F2—systemic lupus erythematosus	1.48e-06	1.15e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—systemic lupus erythematosus	1.47e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.47e-06	1.14e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—systemic lupus erythematosus	1.46e-06	1.14e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—TGFB1—systemic lupus erythematosus	1.46e-06	1.14e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CDKN1A—systemic lupus erythematosus	1.45e-06	1.13e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CD80—systemic lupus erythematosus	1.45e-06	1.13e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EP300—systemic lupus erythematosus	1.45e-06	1.13e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CDKN1A—systemic lupus erythematosus	1.45e-06	1.12e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TYK2—systemic lupus erythematosus	1.43e-06	1.12e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	1.42e-06	1.11e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNG—systemic lupus erythematosus	1.42e-06	1.11e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CD80—systemic lupus erythematosus	1.42e-06	1.1e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EP300—systemic lupus erythematosus	1.42e-06	1.1e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCR5—systemic lupus erythematosus	1.41e-06	1.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EP300—systemic lupus erythematosus	1.41e-06	1.1e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VEGFA—systemic lupus erythematosus	1.41e-06	1.1e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NOS3—systemic lupus erythematosus	1.41e-06	1.09e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—F2—systemic lupus erythematosus	1.4e-06	1.09e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TYK2—systemic lupus erythematosus	1.4e-06	1.09e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2RA—systemic lupus erythematosus	1.39e-06	1.08e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EP300—systemic lupus erythematosus	1.38e-06	1.08e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—C3—systemic lupus erythematosus	1.38e-06	1.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CDKN1A—systemic lupus erythematosus	1.38e-06	1.07e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EP300—systemic lupus erythematosus	1.38e-06	1.07e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS3—systemic lupus erythematosus	1.37e-06	1.07e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ALB—systemic lupus erythematosus	1.37e-06	1.07e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—systemic lupus erythematosus	1.37e-06	1.07e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CDKN1A—systemic lupus erythematosus	1.37e-06	1.07e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TYK2—systemic lupus erythematosus	1.36e-06	1.06e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CDKN1B—systemic lupus erythematosus	1.35e-06	1.05e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	1.35e-06	1.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCL2—systemic lupus erythematosus	1.35e-06	1.05e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CD80—systemic lupus erythematosus	1.34e-06	1.05e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VEGFA—systemic lupus erythematosus	1.34e-06	1.04e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CDKN1B—systemic lupus erythematosus	1.34e-06	1.04e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NOS3—systemic lupus erythematosus	1.33e-06	1.04e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TGFB1—systemic lupus erythematosus	1.33e-06	1.03e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—systemic lupus erythematosus	1.32e-06	1.03e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1.32e-06	1.03e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCL2—systemic lupus erythematosus	1.32e-06	1.03e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—NOS3—systemic lupus erythematosus	1.31e-06	1.02e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—systemic lupus erythematosus	1.31e-06	1.02e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EP300—systemic lupus erythematosus	1.31e-06	1.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EP300—systemic lupus erythematosus	1.3e-06	1.01e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PPARG—systemic lupus erythematosus	1.3e-06	1.01e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TGFB1—systemic lupus erythematosus	1.29e-06	1.01e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CDKN1B—systemic lupus erythematosus	1.29e-06	1e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—RXRA—systemic lupus erythematosus	1.27e-06	9.92e-06	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—systemic lupus erythematosus	1.27e-06	9.91e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—systemic lupus erythematosus	1.27e-06	9.85e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—systemic lupus erythematosus	1.26e-06	9.82e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TGFB1—systemic lupus erythematosus	1.26e-06	9.78e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—systemic lupus erythematosus	1.26e-06	9.78e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—systemic lupus erythematosus	1.25e-06	9.74e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCL2—systemic lupus erythematosus	1.25e-06	9.72e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CDKN1A—systemic lupus erythematosus	1.25e-06	9.7e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—systemic lupus erythematosus	1.24e-06	9.65e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CDKN1A—systemic lupus erythematosus	1.24e-06	9.61e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TGFB1—systemic lupus erythematosus	1.23e-06	9.58e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TYK2—systemic lupus erythematosus	1.22e-06	9.51e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NAT2—systemic lupus erythematosus	1.22e-06	9.49e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CDKN1B—systemic lupus erythematosus	1.22e-06	9.48e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—F2—systemic lupus erythematosus	1.21e-06	9.43e-06	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—systemic lupus erythematosus	1.2e-06	9.35e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—systemic lupus erythematosus	1.2e-06	9.35e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NOS3—systemic lupus erythematosus	1.2e-06	9.33e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TYK2—systemic lupus erythematosus	1.2e-06	9.31e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—systemic lupus erythematosus	1.19e-06	9.28e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—CDKN1B—systemic lupus erythematosus	1.19e-06	9.27e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—CDKN1A—systemic lupus erythematosus	1.19e-06	9.26e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EP300—systemic lupus erythematosus	1.19e-06	9.23e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	1.18e-06	9.2e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EP300—systemic lupus erythematosus	1.18e-06	9.15e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NOS3—systemic lupus erythematosus	1.17e-06	9.14e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ALB—systemic lupus erythematosus	1.17e-06	9.07e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CD80—systemic lupus erythematosus	1.16e-06	9.04e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	1.16e-06	9e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDKN1B—systemic lupus erythematosus	1.15e-06	8.97e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TYK2—systemic lupus erythematosus	1.13e-06	8.83e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—systemic lupus erythematosus	1.13e-06	8.81e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—EP300—systemic lupus erythematosus	1.13e-06	8.81e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—systemic lupus erythematosus	1.13e-06	8.78e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—systemic lupus erythematosus	1.13e-06	8.78e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CDKN1A—systemic lupus erythematosus	1.12e-06	8.75e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—systemic lupus erythematosus	1.12e-06	8.74e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—NOS3—systemic lupus erythematosus	1.12e-06	8.68e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NOS3—systemic lupus erythematosus	1.11e-06	8.66e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—systemic lupus erythematosus	1.11e-06	8.66e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—RXRA—systemic lupus erythematosus	1.11e-06	8.64e-06	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—systemic lupus erythematosus	1.1e-06	8.56e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—CDKN1A—systemic lupus erythematosus	1.1e-06	8.55e-06	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—systemic lupus erythematosus	1.08e-06	8.43e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL2—systemic lupus erythematosus	1.08e-06	8.4e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EP300—systemic lupus erythematosus	1.07e-06	8.33e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—systemic lupus erythematosus	1.07e-06	8.31e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDKN1A—systemic lupus erythematosus	1.06e-06	8.28e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—RXRA—systemic lupus erythematosus	1.05e-06	8.14e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—EP300—systemic lupus erythematosus	1.05e-06	8.14e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1B—systemic lupus erythematosus	1.04e-06	8.09e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—RXRA—systemic lupus erythematosus	1.04e-06	8.07e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—systemic lupus erythematosus	1.03e-06	8.03e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—systemic lupus erythematosus	1.03e-06	7.98e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—systemic lupus erythematosus	1.02e-06	7.95e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—systemic lupus erythematosus	1.02e-06	7.94e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1B—systemic lupus erythematosus	1.02e-06	7.92e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—systemic lupus erythematosus	1.02e-06	7.91e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—systemic lupus erythematosus	1.01e-06	7.88e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EP300—systemic lupus erythematosus	1.01e-06	7.88e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—systemic lupus erythematosus	1e-06	7.79e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—EP300—systemic lupus erythematosus	1e-06	7.78e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—systemic lupus erythematosus	9.96e-07	7.75e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TYK2—systemic lupus erythematosus	9.81e-07	7.63e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—systemic lupus erythematosus	9.76e-07	7.59e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1B—systemic lupus erythematosus	9.65e-07	7.5e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—systemic lupus erythematosus	9.63e-07	7.49e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—systemic lupus erythematosus	9.63e-07	7.49e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	9.62e-07	7.49e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—systemic lupus erythematosus	9.59e-07	7.46e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1A—systemic lupus erythematosus	9.59e-07	7.46e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—systemic lupus erythematosus	9.51e-07	7.4e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—systemic lupus erythematosus	9.48e-07	7.37e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—systemic lupus erythematosus	9.44e-07	7.34e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—systemic lupus erythematosus	9.42e-07	7.33e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1A—systemic lupus erythematosus	9.39e-07	7.31e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—systemic lupus erythematosus	9.3e-07	7.24e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—systemic lupus erythematosus	9.28e-07	7.22e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—systemic lupus erythematosus	9.25e-07	7.19e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EP300—systemic lupus erythematosus	9.13e-07	7.1e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—systemic lupus erythematosus	9.09e-07	7.07e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—systemic lupus erythematosus	9.05e-07	7.04e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—systemic lupus erythematosus	9.01e-07	7.01e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EP300—systemic lupus erythematosus	8.94e-07	6.95e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—systemic lupus erythematosus	8.93e-07	6.95e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1A—systemic lupus erythematosus	8.9e-07	6.93e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—systemic lupus erythematosus	8.81e-07	6.85e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—systemic lupus erythematosus	8.64e-07	6.72e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—systemic lupus erythematosus	8.58e-07	6.68e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—systemic lupus erythematosus	8.55e-07	6.65e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—systemic lupus erythematosus	8.54e-07	6.64e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—EP300—systemic lupus erythematosus	8.49e-07	6.6e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EP300—systemic lupus erythematosus	8.47e-07	6.59e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—systemic lupus erythematosus	8.46e-07	6.58e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1B—systemic lupus erythematosus	8.34e-07	6.49e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—systemic lupus erythematosus	8.18e-07	6.36e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—systemic lupus erythematosus	8.16e-07	6.35e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—systemic lupus erythematosus	8.05e-07	6.26e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—systemic lupus erythematosus	8.02e-07	6.24e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—systemic lupus erythematosus	7.93e-07	6.17e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—systemic lupus erythematosus	7.77e-07	6.05e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—systemic lupus erythematosus	7.77e-07	6.04e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—systemic lupus erythematosus	7.72e-07	6.01e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—systemic lupus erythematosus	7.7e-07	5.99e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1A—systemic lupus erythematosus	7.7e-07	5.99e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—systemic lupus erythematosus	7.48e-07	5.82e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—systemic lupus erythematosus	7.42e-07	5.77e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—systemic lupus erythematosus	7.36e-07	5.73e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EP300—systemic lupus erythematosus	7.32e-07	5.7e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—systemic lupus erythematosus	7.24e-07	5.63e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—systemic lupus erythematosus	7.01e-07	5.45e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—systemic lupus erythematosus	7.01e-07	5.45e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—systemic lupus erythematosus	6.94e-07	5.4e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—systemic lupus erythematosus	6.92e-07	5.39e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—systemic lupus erythematosus	6.85e-07	5.33e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—RXRA—systemic lupus erythematosus	6.84e-07	5.32e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—systemic lupus erythematosus	6.64e-07	5.16e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—systemic lupus erythematosus	6.61e-07	5.14e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—systemic lupus erythematosus	6.55e-07	5.1e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—systemic lupus erythematosus	6.37e-07	4.95e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—systemic lupus erythematosus	6.33e-07	4.93e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—systemic lupus erythematosus	6.3e-07	4.9e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—EP300—systemic lupus erythematosus	6.22e-07	4.84e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—systemic lupus erythematosus	6.03e-07	4.69e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—systemic lupus erythematosus	5.98e-07	4.65e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—systemic lupus erythematosus	5.94e-07	4.62e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—systemic lupus erythematosus	5.89e-07	4.58e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—systemic lupus erythematosus	5.85e-07	4.55e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—systemic lupus erythematosus	5.68e-07	4.42e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—systemic lupus erythematosus	5.63e-07	4.38e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—systemic lupus erythematosus	5.55e-07	4.32e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—systemic lupus erythematosus	5.52e-07	4.29e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—EP300—systemic lupus erythematosus	5.27e-07	4.1e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—systemic lupus erythematosus	5.2e-07	4.04e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—systemic lupus erythematosus	5.15e-07	4.01e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—systemic lupus erythematosus	4.8e-07	3.73e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—EP300—systemic lupus erythematosus	4.59e-07	3.57e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—EP300—systemic lupus erythematosus	4.32e-07	3.36e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—systemic lupus erythematosus	4.32e-07	3.36e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—EP300—systemic lupus erythematosus	4.29e-07	3.33e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—systemic lupus erythematosus	3.88e-07	3.02e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—systemic lupus erythematosus	3.72e-07	2.89e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—systemic lupus erythematosus	3.4e-07	2.64e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—EP300—systemic lupus erythematosus	2.83e-07	2.2e-06	CbGpPWpGaD
